Full Press Release Details
the Functional Loss in Parkinson's and Related Disorders 2Q 2021 BUSINESS PRESENTATIONExhibit 99.1 IKT Clinical Development of Therapies Intended to Reverse the Functional Loss in Parkinson's and Related Disorders 2Q 2021 BUSINESS
Disclaimer This presentation shall not constitute an offer to sell or a
solicitation of an offer to buy any securities, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws
of any such state or jurisdiction. This presentation contains information that may constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934,
as amended. Inhibikase Therapeutics, Inc. (the "Company" or "we") intends for the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements in those sections. Generally, we have
identified such forward-looking statements by using the words "believe," "expect," "intend," "estimate," "anticipate," "project," "target," "forecast,"
"aim," should, "will," may", "continue" and similar expressions. Such statements are subject to a number of assumptions, risks and uncertainties which may cause actual results, performance or achievements to
be materially different from those anticipated in these forward-looking statements. You should read statements that contain these words carefully because they discuss future expectations and plans which contain projections of future clinical
studies, regulatory approvals, product candidate development, results of operations or financial condition or state other forward-looking information. However, the absence of these words or similar expressions does not mean that a statement is not
forward-looking. Forward-looking statements are not historical facts, but instead represent only the Company's beliefs regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's
control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Management believes that
these forward-looking statements are reasonable as of the time made. However, caution should be taken not to place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. The Company
undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks
and uncertainties that could cause actual results to differ materially from the Company's historical experience and our present expectations or projections. Important factors that could cause actual results to differ materially from those in the
forward-looking statements are set forth in the Company's filings with the Securities and Exchange Commission, including its registration statement on Form S-1, as amended (File No. 333-240036), including under the caption Risk Factors. We do
not intend our use or display of other entities' names, trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entity. 22Disclaimer This presentation shall not constitute an
offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under
the securities laws of any such state or jurisdiction. This presentation contains information that may constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act, and Section 21E of the Securities
Exchange Act of 1934, as amended. Inhibikase Therapeutics, Inc. (the "Company" or "we") intends for the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements in those sections.
Generally, we have identified such forward-looking statements by using the words "believe," "expect," "intend," "estimate," "anticipate," "project," "target,"
"forecast," "aim," should, "will," may", "continue" and similar expressions. Such statements are subject to a number of assumptions, risks and uncertainties which may cause actual results,
performance or achievements to be materially different from those anticipated in these forward-looking statements. You should read statements that contain these words carefully because they discuss future expectations and plans which contain
projections of future clinical studies, regulatory approvals, product candidate development, results of operations or financial condition or state other forward-looking information. However, the absence of these words or similar expressions does not
mean that a statement is not forward-looking. Forward-looking statements are not historical facts, but instead represent only the Company's beliefs regarding future events, many of which, by their nature, are inherently uncertain and outside
of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements.
Management believes that these forward-looking statements are reasonable as of the time made. However, caution should be taken not to place undue reliance on any such forward-looking statements because such statements speak only as of the date when
made. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are
subject to certain risks and uncertainties that could cause actual results to differ materially from the Company's historical experience and our present expectations or projections. Important factors that could cause actual results to differ
materially from those in the forward-looking statements are set forth in the Company's filings with the Securities and Exchange Commission, including its registration statement on Form S-1, as amended (File No. 333-240036), including under the
caption Risk Factors. We do not intend our use or display of other entities' names, trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entity. 22
IKT Company OverviewIKT Company Overview
COMPANY HIGHLIGHTS Driving Functional Reversal of Parkinson's
Disease BY 2025, PARKINSON'S DISEASE Multi-therapeutic pipeline with emphasis on neurodegeneration inside and out DRUG SALES ARE EXPECTED TO side of the brain Our lead inhibitor of the Abelson Tyrosine Kinase (c-Abl), IkT-148009,
halts and Double Pharma Insights, 2019 reverses functional loss in animal models that recreate progressive human disease SALES ESTIMATES BY Five clinical programs in neurodegeneration and one clinical program in 2025 ARE EXPECTED TO oncology
by close of 2021 CREST Ongoing Phase 1 trial with IkT-148009 reaches therapeutic drug exposures seen in $6.0 Billion animal models at just 25 mg oral dose 1x/day in humans Pharma Insights, 2019 Multiple patent families for lead
compound with expiration of 2036 and beyond $20.4 million in grants and contracts from NIH, DoD, the Michael J. Fox Foundation and the Georgia Research Alliance, all peer-reviewed THE COUNTRY WITH THE HIGHEST DIAGNOSED PREVALENCE IS
$19 million in investor capital since 2018 Highly experienced and respected management team, consultants, Board of The U.S. DelveInsight, 2019 Directors and nearly all KOLs in the field on Scientific Advisory Board 4 4COMPANY HIGHLIGHTS
Driving Functional Reversal of Parkinson's Disease BY 2025, PARKINSON'S DISEASE Multi-therapeutic pipeline with emphasis on neurodegeneration inside and out DRUG SALES ARE EXPECTED TO side of the brain Our lead inhibitor of
the Abelson Tyrosine Kinase (c-Abl), IkT-148009, halts and Double Pharma Insights, 2019 reverses functional loss in animal models that recreate progressive human disease SALES ESTIMATES BY Five clinical programs in neurodegeneration and one
clinical program in 2025 ARE EXPECTED TO oncology by close of 2021 CREST Ongoing Phase 1 trial with IkT-148009 reaches therapeutic drug exposures seen in $6.0 Billion animal models at just 25 mg oral dose 1x/day in humans Pharma Insights,
2019 Multiple patent families for lead compound with expiration of 2036 and beyond $20.4 million in grants and contracts from NIH, DoD, the Michael J. Fox Foundation and the Georgia Research Alliance, all peer-reviewed THE COUNTRY WITH
THE HIGHEST DIAGNOSED PREVALENCE IS $19 million in investor capital since 2018 Highly experienced and respected management team, consultants, Board of The U.S. DelveInsight, 2019 Directors and nearly all KOLs in the field on Scientific
COMPANY HIGHLIGHTS: MULTI-THERAPEUTIC PIPELINE Multi-Indication Pipeline
in Neurodegeneration, Oncology and Infectious Disease 5COMPANY HIGHLIGHTS: MULTI-THERAPEUTIC PIPELINE Multi-Indication Pipeline in Neurodegeneration, Oncology and Infectious Disease 5
COMPANY HIGHLIGHTS Selected Financial and Stock Data $20.4M
non-dilutive grant revenue pre-IPO (NIH, DoD, States) $19M equity sales since 2018, $18M from Initial Public Offering with ThinkEquity 10,133,345 issued and outstanding common shares as of 5/14/2021 3,574,658 Options (WAEP
$2.43) 721,913 Warrants (WAEP $5.83) 53% held by insiders, 16.5% held by institutions March 31, Balance Sheet 2021 Current assets: Cash $ 9,609,631 Grants Receivable 332,674 Prepaid research and development 712,674 Prepaid expenses and
other current assets 1,218,956 Total Current Assets $ 11,874,035 Total Current Liabilities 3,837,464 Working Capital 8,036,5717 Active grant funding available in accounts held by U.S. Treasury 772,420 Total Working Capital $ 8,808,991 6 6 6COMPANY
HIGHLIGHTS Selected Financial and Stock Data $20.4M non-dilutive grant revenue pre-IPO (NIH, DoD, States) $19M equity sales since 2018, $18M from Initial Public Offering with ThinkEquity 10,133,345 issued and outstanding common
shares as of 5/14/2021 3,574,658 Options (WAEP $2.43) 721,913 Warrants (WAEP $5.83) 53% held by insiders, 16.5% held by institutions March 31, Balance Sheet 2021 Current assets: Cash $ 9,609,631 Grants Receivable 332,674 Prepaid
research and development 712,674 Prepaid expenses and other current assets 1,218,956 Total Current Assets $ 11,874,035 Total Current Liabilities 3,837,464 Working Capital 8,036,5717 Active grant funding available in accounts held by U.S. Treasury
772,420 Total Working Capital $ 8,808,991 6 6 6
ONGOING TRIALS IN SAFETY AND DOSING Accelerated Clinical Development
Timeline Pre-IPO plan, Dec. 2020 Sequential Single Ascending Dose (SAD) in 8 cohorts, followed by Multiple Ascending Dose (MAD) in 4 cohorts PD patients in late 4Q21 or 1Q22 Phase 1b (Overlapping, Up to 6 Months) Phase 1 SAD / MAD (12-14 Months) 1 2
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 u MONTHS Phase 1b (Overlapping, Up to 6 Months) Phase 1 SAD / MAD (6-7 Months) Accelerated plan, Mar. 2021 Interleaving SAD and MAD cohorts, reducing Phase 1 duration by 6+ months MAD cohorts of PD patients
added to protocol and under FDA regulatory review. Anticipated enrollments in early 3Q21 7ONGOING TRIALS IN SAFETY AND DOSING Accelerated Clinical Development Timeline Pre-IPO plan, Dec. 2020 Sequential Single Ascending Dose (SAD) in 8 cohorts,
followed by Multiple Ascending Dose (MAD) in 4 cohorts PD patients in late 4Q21 or 1Q22 Phase 1b (Overlapping, Up to 6 Months) Phase 1 SAD / MAD (12-14 Months) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 u MONTHS Phase 1b (Overlapping, Up to 6
Months) Phase 1 SAD / MAD (6-7 Months) Accelerated plan, Mar. 2021 Interleaving SAD and MAD cohorts, reducing Phase 1 duration by 6+ months MAD cohorts of PD patients added to protocol and under FDA regulatory review. Anticipated enrollments in
IKT Parkinson's Disease Market & Strategy IKT
Parkinson's Disease Market & Strategy
THE MARKET 1 Parkinson's Disease in the U.S. Large Market,
Opportunity For Disease Modification Chronic Disease for a Long Time 700,000 - 1,000,000 1/3 of a Patient's Lifespan = 25 years U.S. Patients 60,000 38,000 60 DEATHS / YEAR NEW CASES / YR AVERAGE AGE OF ONSET Other illnesses complicate
development Men twice as likely as women to contract disease 36% 35% 30% 47% ARTHRITIS HEART / CIRCULATORY PSYCHOSIS DEMENTIA Parkinson's Disease Foundation Decisions Resources 2016, ParkinsonismRelatDisord . 2012;18:1073-1078, ,
Neuroepidemiology 2010;34:143-151 , J Neurol Neurosurg Psychiatry. 1997 Jan;62(1):10-5. 9THE MARKET 1 Parkinson's Disease in the U.S. Large Market, Opportunity For Disease Modification Chronic Disease for a Long Time 700,000 -
1,000,000 1/3 of a Patient's Lifespan = 25 years U.S. Patients 60,000 38,000 60 DEATHS / YEAR NEW CASES / YR AVERAGE AGE OF ONSET Other illnesses complicate development Men twice as likely as women to contract disease 36% 35% 30% 47% ARTHRITIS
HEART / CIRCULATORY PSYCHOSIS DEMENTIA Parkinson's Disease Foundation Decisions Resources 2016, ParkinsonismRelatDisord . 2012;18:1073-1078, , Neuroepidemiology 2010;34:143-151 , J Neurol Neurosurg Psychiatry. 1997 Jan;62(1):10-5.
HOW THE GI TRACT ILLUMINATES A NOVEL WAY TO TREAT PATIENTS Model
studies suggest the gut could be where Parkinson's disease originates in the body and is a critical organ for analysis The Gut-Brain Connection Enables Innovation in Trial Design Parkinson's May Begin in the Gut Easy access Can
demonstrate disease benefit with quantitative endpoints Biopsy and Biomarkers Large effect size GI disorders resulting from kinase a modification of -synuclein: Dysphagia Unresolvable constipation Gastroesophageal reflux Gastroparesis Introduction
of dysfunctional synuclein in the gut leads to progressive disease that mirrors the human disease course in the brain 10HOW THE GI TRACT ILLUMINATES A NOVEL WAY TO TREAT PATIENTS Model studies suggest the gut could be where Parkinson's disease
originates in the body and is a critical organ for analysis The Gut-Brain Connection Enables Innovation in Trial Design Parkinson's May Begin in the Gut Easy access Can demonstrate disease benefit with quantitative endpoints Biopsy and
Biomarkers Large effect size GI disorders resulting from kinase a modification of -synuclein: Dysphagia Unresolvable constipation Gastroesophageal reflux Gastroparesis Introduction of dysfunctional synuclein in the gut leads to progressive disease
that mirrors the human disease course in the brain 10
IKT Causation of Parkinson's and How Inhibikase Proposes to
Modify DiseaseIKT Causation of Parkinson's and How Inhibikase Proposes to Modify Disease
NEURODEGENERATION Investigating Causation in Parkinson's Reveals
c- Abl as a Primary Culprit Parkinson's Disease (PD) is a neurodegenerative disease which limits function of nerve cells throughout the brain and gut. PD conditions include: Tremors Slowed Movement Impaired Balance Permanent
Constipation Speech Loss Cognitive Decline Memory Loss and Reflux Disease -Synuclein Is normally in a helix- 1 turn-helix configuration -Synuclein, an abundant and non-essential protein, has long been thought to be linked to the
cause of Parkinson's Disease Normally, -Synuclein plays a role in neurotransmission by dopamine. In the disease state, -Synuclein is remodeled into protein aggregates we call plaques, which have been thought to be the
cause of disease. The Company and it's collaborators have demonstrated that plaques of - synuclein cannot cause disease on their own. Plaques are internalized and activate c-Abl. In the disease state, -Synuclein
reorganizes to form fibrous aggregates c-Abl is actually driving the disease. 2 ("Plaques") 1 Biochim Biophys Acta. 1818:1013-8 (2012) 2 Pathogens 7:50 (2018) 12NEURODEGENERATION Investigating Causation in Parkinson's
Reveals c- Abl as a Primary Culprit Parkinson's Disease (PD) is a neurodegenerative disease which limits function of nerve cells throughout the brain and gut. PD conditions include: Tremors Slowed Movement Impaired Balance
Permanent Constipation Speech Loss Cognitive Decline Memory Loss and Reflux Disease -Synuclein Is normally in a helix- 1 turn-helix configuration -Synuclein, an abundant and non-essential protein, has long been thought to be
linked to the cause of Parkinson's Disease Normally, -Synuclein plays a role in neurotransmission by dopamine. In the disease state, -Synuclein is remodeled into protein aggregates we call plaques, which have been
thought to be the cause of disease. The Company and it's collaborators have demonstrated that plaques of - synuclein cannot cause disease on their own. Plaques are internalized and activate c-Abl. In the disease state,
-Synuclein reorganizes to form fibrous aggregates c-Abl is actually driving the disease. 2 ("Plaques") 1 Biochim Biophys Acta. 1818:1013-8 (2012) 2 Pathogens 7:50 (2018) 12
CE L L E N T R Y THE PATH TO NEURODEGENERATION Stressors Trigger the
Production of -Synuclein Plaques Which Activates c-Abl to Drive Neurodegeneration 1 The Effects and Stressors Trigger -Synuclein Forms C-Abl is a Sentinel which Patrols for NEURODEGENERATION Results of Activated Abnormalities the
Production of Fibrous Aggregates we call c-Abl Kinase Inside a Gut or Brain Neuron -Synuclein Plaques Sensing -synuclein c-Abl's sensor GI Conditions Oxidative / Plaques of misfolded - plaques, activated c-Abl identifies
nitrosative stress synuclein are abnormal, Chemically Modifies - but benign -synuclein plaques Parkinson's 39 Point mutation in one or synuclein at Tyr (pY39), as a threat and Disease more proteins causing converting it into its
toxic, activates in response hyperaggregation pathologic form (Mutant -syn, LRRK2, Treatment at this stage 3 GBA1) is ineffective C-Abl further chemically modifies Parkin, disrupting -synuclein mitochondrial integrity and duplication /
triplication survival pathways that could clear -synuclein toxicity 1 Nat Rev Neurosci. 2, 492-501 (2001) 2 Werner and Olanow (2021), under review 3
https://ir.prothena.com/news-releases/news-release-details/update-phase-2-pasadena-study-prasinezumab-prx002rg7935 13 http://media.biogen.com/node/22876/htmlCE L L E N T R Y THE PATH TO NEURODEGENERATION Stressors Trigger the Production of
-Synuclein Plaques Which Activates c-Abl to Drive Neurodegeneration 1 The Effects and Stressors Trigger -Synuclein Forms C-Abl is a Sentinel which Patrols for NEURODEGENERATION Results of Activated Abnormalities the Production of Fibrous
Aggregates we call c-Abl Kinase Inside a Gut or Brain Neuron -Synuclein Plaques Sensing -synuclein c-Abl's sensor GI Conditions Oxidative / Plaques of misfolded - plaques, activated c-Abl identifies nitrosative stress
synuclein are abnormal, Chemically Modifies - but benign -synuclein plaques Parkinson's 39 Point mutation in one or synuclein at Tyr (pY39), as a threat and Disease more proteins causing converting it into its toxic, activates in
response hyperaggregation pathologic form (Mutant -syn, LRRK2, Treatment at this stage 3 GBA1) is ineffective C-Abl further chemically modifies Parkin, disrupting -synuclein mitochondrial integrity and duplication / triplication survival
pathways that could clear -synuclein toxicity 1 Nat Rev Neurosci. 2, 492-501 (2001) 2 Werner and Olanow (2021), under review 3
INHIBIKASE'S PROOF ACTIVATED C-ABL IS THE GATEWAY IN THE DISEASE